RxDoctor Payments Data

Navid Shams Javani, MD

Family Medicine · Fleming Island, FLNPI 1790104800

Payments from drug & device makers

$945in general payments, 2019–2025

Across 17 payments — averaging $55.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$252
  • Novo Nordisk$245
  • Recor Medical Inc$161
  • Boston Scientific$86
  • AbbVie$63
  • Dynavax Technologies Corporation$57
  • plus $80 from 3 others

What the payments were for

  • Food & beverage$945100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$945 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$128,381
Medicare patients
309
Services billed
1,432

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin81$102,847
OzempicSemaglutide57$90,644
RybelsusSemaglutide15$25,918
MounjaroTirzepatide14$24,958
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$18,269
MyrbetriqMirabegron11$15,477
FarxigaDapagliflozin Propanediol14$11,746
Atorvastatin Calcium445$4,491
Rosuvastatin Calcium207$2,413
Levothyroxine Sodium199$2,387
SynthroidLevothyroxine Sodium19$2,229
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,001
Metoprolol Succinate113$1,944
Losartan Potassium193$1,637
Lisinopril196$1,612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$245$116,56272 claims
GSKTrelegy Ellipta$13$18,26912 claims
AbbVieSynthroid$63$2,22919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Fleming Island

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →